The quarterly report and presentation will be published at 07:00 CET on November 6, 2024, and will be publicly available on the Ultimovacs website. The Company will conduct a conference call and webcast at 14:00 CET the same day. Questions can be submitted throughout the event. The webcast will be archived for replay following the conference call. Link to webcast here.
Ultimovacs Reports Third Quarter 2024 Financial Results and Provides General Business Update on November 6
Sign up for company news
Press Releases
Ultimovacs ASA Reports Third Quarter 2024 Financial Results and Provides General Business Update
6, November, 2024
Ultimovacs Announces Patient Recruitment Discontinuation in LUNGVAC Trial Investigating UV1 Combined with Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer
11, September, 2024
Ultimovacs Announces Updated Data Analysis on UV1 Phase II NIPU Trial in Mesothelioma at ESMO 2024
9, September, 2024
Ultimovacs ASA Reports Second Quarter 2024 Financial Results and Provides General Business Update
21, August, 2024
See all
News
Interview with CEO Carlos de Sousa in Finansavisen TV
14, February, 2024
Biostock Article: About the NIPU study and interview with the Director of Medical Affairs at Ultimovacs, Espen Basmo Ellingsen
6, June, 2023
Ultimovacs Presentation at TD Cowen Healthcare Conference
6, March, 2023
Article published in Current Opinion in Oncology: “Therapeutic cancer vaccination against telomerase”
8, February, 2023
See all